Expect to See More Biologics Used to Treat Severe Asthma

We're getting questions about using omalizumab (Xolair) or other biologics for SEVERE asthma.

These meds reduce inflammation and asthma symptoms by targeting certain mediators...IgE for omalizumab, or interleukin-5 for mepolizumab (Nucala), reslizumab (Cinqair), and benralizumab (Fasenra).

These injectable meds cost between $13,000 and $30,000/year...and are given in a healthcare setting equipped to manage anaphylaxis.

Get unlimited access through an Enterprise license

Hospital Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Not sold to individuals